Clinically, it works very well in shrinking lymph node size. Many of the patients who are responders are partial responders, meaning that there's still some measurable disease, which is usually in the bone marrow or blood. Venetoclax is highly effective at killing CLL cells and is...
Dr van Meerten on the Efficacy and Safety of Brexu-Cel in BTK Inhibitor–Naive R/R MCL Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL ...
In terms of del(11q), this is where you have to think about the patient population. If you are thinking about giving a targeted agent to patients, del(11q) probably does not have any meaning anymore. Ibrutinib completely overcomes that. It also completely overcomes theIGHVstatus,...